JP7011885B2 - 腸の健康を促す組成物 - Google Patents
腸の健康を促す組成物 Download PDFInfo
- Publication number
- JP7011885B2 JP7011885B2 JP2019545873A JP2019545873A JP7011885B2 JP 7011885 B2 JP7011885 B2 JP 7011885B2 JP 2019545873 A JP2019545873 A JP 2019545873A JP 2019545873 A JP2019545873 A JP 2019545873A JP 7011885 B2 JP7011885 B2 JP 7011885B2
- Authority
- JP
- Japan
- Prior art keywords
- composition
- component
- extract component
- composition according
- intestinal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims description 333
- 230000007413 intestinal health Effects 0.000 title claims description 19
- 235000010208 anthocyanin Nutrition 0.000 claims description 139
- 229930002877 anthocyanin Natural products 0.000 claims description 139
- 239000004410 anthocyanin Substances 0.000 claims description 139
- 150000004636 anthocyanins Chemical class 0.000 claims description 139
- 235000017537 Vaccinium myrtillus Nutrition 0.000 claims description 114
- 239000000284 extract Substances 0.000 claims description 87
- VEVZSMAEJFVWIL-UHFFFAOYSA-O cyanidin Natural products [O+]=1C2=CC(O)=CC(O)=C2C=C(O)C=1C1=CC=C(O)C(O)=C1 VEVZSMAEJFVWIL-UHFFFAOYSA-O 0.000 claims description 77
- 241000371652 Curvularia clavata Species 0.000 claims description 68
- 235000001466 Ribes nigrum Nutrition 0.000 claims description 64
- 240000001890 Ribes hudsonianum Species 0.000 claims description 61
- 235000016954 Ribes hudsonianum Nutrition 0.000 claims description 61
- 241000194010 Empetrum Species 0.000 claims description 55
- 230000000968 intestinal effect Effects 0.000 claims description 54
- 235000012778 Empetrum nigrum Nutrition 0.000 claims description 52
- 235000007336 cyanidin Nutrition 0.000 claims description 44
- 235000007242 delphinidin Nutrition 0.000 claims description 43
- 229920001202 Inulin Polymers 0.000 claims description 42
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 42
- 229940029339 inulin Drugs 0.000 claims description 42
- GCPYCNBGGPHOBD-UHFFFAOYSA-N Delphinidin Natural products OC1=Cc2c(O)cc(O)cc2OC1=C3C=C(O)C(=O)C(=C3)O GCPYCNBGGPHOBD-UHFFFAOYSA-N 0.000 claims description 39
- 235000013406 prebiotics Nutrition 0.000 claims description 35
- 244000078534 Vaccinium myrtillus Species 0.000 claims description 29
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims description 22
- 229940107187 fructooligosaccharide Drugs 0.000 claims description 22
- 230000003870 intestinal permeability Effects 0.000 claims description 17
- 239000002994 raw material Substances 0.000 claims description 15
- 235000019216 blueberry extract Nutrition 0.000 claims description 14
- 229940055416 blueberry extract Drugs 0.000 claims description 14
- -1 cyanidin glycoside Chemical class 0.000 claims description 12
- 229930182470 glycoside Natural products 0.000 claims description 9
- 244000298479 Cichorium intybus Species 0.000 claims description 7
- 235000007542 Cichorium intybus Nutrition 0.000 claims description 7
- 235000019209 bilberry extract Nutrition 0.000 claims description 7
- 229940102480 bilberry extract Drugs 0.000 claims description 7
- 241001312569 Ribes nigrum Species 0.000 claims description 3
- BJHIKXHVCXFQLS-UYFOZJQFSA-N fructose group Chemical group OCC(=O)[C@@H](O)[C@H](O)[C@H](O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 claims description 3
- 150000004676 glycans Chemical class 0.000 claims description 3
- 229920001542 oligosaccharide Polymers 0.000 claims description 3
- 150000002482 oligosaccharides Chemical class 0.000 claims description 3
- 229920001282 polysaccharide Polymers 0.000 claims description 3
- 239000005017 polysaccharide Substances 0.000 claims description 3
- 235000021028 berry Nutrition 0.000 claims description 2
- 238000000034 method Methods 0.000 description 142
- 244000077233 Vaccinium uliginosum Species 0.000 description 89
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 86
- 235000021014 blueberries Nutrition 0.000 description 86
- 239000006186 oral dosage form Substances 0.000 description 54
- 235000005911 diet Nutrition 0.000 description 48
- 230000037213 diet Effects 0.000 description 45
- 241000894006 Bacteria Species 0.000 description 44
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 40
- 201000010099 disease Diseases 0.000 description 39
- 241000699670 Mus sp. Species 0.000 description 36
- JKHRCGUTYDNCLE-UHFFFAOYSA-O delphinidin Chemical compound [O+]=1C2=CC(O)=CC(O)=C2C=C(O)C=1C1=CC(O)=C(O)C(O)=C1 JKHRCGUTYDNCLE-UHFFFAOYSA-O 0.000 description 36
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 34
- 230000001965 increasing effect Effects 0.000 description 34
- 210000001578 tight junction Anatomy 0.000 description 31
- 239000000843 powder Substances 0.000 description 30
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 29
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 29
- 235000009200 high fat diet Nutrition 0.000 description 26
- 230000000813 microbial effect Effects 0.000 description 24
- 230000002496 gastric effect Effects 0.000 description 23
- 230000009467 reduction Effects 0.000 description 23
- 102000000591 Tight Junction Proteins Human genes 0.000 description 22
- 108010002321 Tight Junction Proteins Proteins 0.000 description 22
- 210000002919 epithelial cell Anatomy 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 20
- 230000002354 daily effect Effects 0.000 description 20
- 239000004615 ingredient Substances 0.000 description 20
- 206010061218 Inflammation Diseases 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 18
- 238000009472 formulation Methods 0.000 description 18
- 210000001035 gastrointestinal tract Anatomy 0.000 description 18
- 230000004054 inflammatory process Effects 0.000 description 18
- 230000036541 health Effects 0.000 description 17
- 239000000126 substance Substances 0.000 description 17
- 241000606125 Bacteroides Species 0.000 description 16
- 208000008589 Obesity Diseases 0.000 description 16
- 241000700159 Rattus Species 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 16
- 235000020824 obesity Nutrition 0.000 description 16
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 16
- 229920002307 Dextran Polymers 0.000 description 15
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 15
- 239000003814 drug Substances 0.000 description 15
- 235000013399 edible fruits Nutrition 0.000 description 15
- 244000005709 gut microbiome Species 0.000 description 15
- 230000035699 permeability Effects 0.000 description 15
- 230000002829 reductive effect Effects 0.000 description 15
- 230000032258 transport Effects 0.000 description 15
- 239000002158 endotoxin Substances 0.000 description 14
- 235000013305 food Nutrition 0.000 description 14
- KZMACGJDUUWFCH-UHFFFAOYSA-O malvidin Chemical compound COC1=C(O)C(OC)=CC(C=2C(=CC=3C(O)=CC(O)=CC=3[O+]=2)O)=C1 KZMACGJDUUWFCH-UHFFFAOYSA-O 0.000 description 14
- 239000000463 material Substances 0.000 description 14
- 229940079593 drug Drugs 0.000 description 13
- 206010022489 Insulin Resistance Diseases 0.000 description 12
- 235000013339 cereals Nutrition 0.000 description 12
- 235000008504 concentrate Nutrition 0.000 description 12
- 239000012141 concentrate Substances 0.000 description 12
- 230000002526 effect on cardiovascular system Effects 0.000 description 12
- 239000002609 medium Substances 0.000 description 12
- 230000000770 proinflammatory effect Effects 0.000 description 12
- 239000002356 single layer Substances 0.000 description 12
- 240000005662 Aronia melanocarpa Species 0.000 description 11
- 235000007425 Aronia melanocarpa Nutrition 0.000 description 11
- 235000013361 beverage Nutrition 0.000 description 11
- 230000006872 improvement Effects 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- LYPFDBRUNKHDGX-SOGSVHMOSA-N N1C2=CC=C1\C(=C1\C=CC(=N1)\C(=C1\C=C/C(/N1)=C(/C1=N/C(/CC1)=C2/C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\C1=CC(O)=CC=C1)C1=CC(O)=CC=C1 Chemical compound N1C2=CC=C1\C(=C1\C=CC(=N1)\C(=C1\C=C/C(/N1)=C(/C1=N/C(/CC1)=C2/C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\C1=CC(O)=CC=C1)C1=CC(O)=CC=C1 LYPFDBRUNKHDGX-SOGSVHMOSA-N 0.000 description 10
- 230000009286 beneficial effect Effects 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 230000003247 decreasing effect Effects 0.000 description 10
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 10
- 210000005095 gastrointestinal system Anatomy 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 230000004048 modification Effects 0.000 description 10
- 238000012986 modification Methods 0.000 description 10
- 229960002197 temoporfin Drugs 0.000 description 10
- 230000004044 response Effects 0.000 description 9
- 230000009469 supplementation Effects 0.000 description 9
- 102100025255 Haptoglobin Human genes 0.000 description 8
- 102000004877 Insulin Human genes 0.000 description 8
- 108090001061 Insulin Proteins 0.000 description 8
- 230000004888 barrier function Effects 0.000 description 8
- 239000013553 cell monolayer Substances 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 239000000835 fiber Substances 0.000 description 8
- 229940125396 insulin Drugs 0.000 description 8
- 239000010410 layer Substances 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- 230000036961 partial effect Effects 0.000 description 8
- 210000000813 small intestine Anatomy 0.000 description 8
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 8
- 108010027843 zonulin Proteins 0.000 description 8
- 206010000060 Abdominal distension Diseases 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 7
- 206010016766 flatulence Diseases 0.000 description 7
- 235000009584 malvidin Nutrition 0.000 description 7
- 229930015721 peonidin Natural products 0.000 description 7
- 235000006404 peonidin Nutrition 0.000 description 7
- XFDQJKDGGOEYPI-UHFFFAOYSA-O peonidin Chemical compound C1=C(O)C(OC)=CC(C=2C(=CC=3C(O)=CC(O)=CC=3[O+]=2)O)=C1 XFDQJKDGGOEYPI-UHFFFAOYSA-O 0.000 description 7
- 229930015717 petunidin Natural products 0.000 description 7
- 235000006384 petunidin Nutrition 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 210000002700 urine Anatomy 0.000 description 7
- 102000001109 Leukocyte L1 Antigen Complex Human genes 0.000 description 6
- 108010069316 Leukocyte L1 Antigen Complex Proteins 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 210000001072 colon Anatomy 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 231100000673 dose–response relationship Toxicity 0.000 description 6
- 230000002550 fecal effect Effects 0.000 description 6
- 229930003935 flavonoid Natural products 0.000 description 6
- 150000002215 flavonoids Chemical class 0.000 description 6
- 235000017173 flavonoids Nutrition 0.000 description 6
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 210000000936 intestine Anatomy 0.000 description 6
- 210000002429 large intestine Anatomy 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 235000015097 nutrients Nutrition 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- AFOLOMGWVXKIQL-UHFFFAOYSA-O petunidin Chemical compound OC1=C(O)C(OC)=CC(C=2C(=CC=3C(O)=CC(O)=CC=3[O+]=2)O)=C1 AFOLOMGWVXKIQL-UHFFFAOYSA-O 0.000 description 6
- 241000186361 Actinobacteria <class> Species 0.000 description 5
- 206010009900 Colitis ulcerative Diseases 0.000 description 5
- 208000001145 Metabolic Syndrome Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 201000006704 Ulcerative Colitis Diseases 0.000 description 5
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 5
- 230000002411 adverse Effects 0.000 description 5
- 208000006673 asthma Diseases 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 235000005487 catechin Nutrition 0.000 description 5
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 235000012734 epicatechin Nutrition 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 210000005027 intestinal barrier Anatomy 0.000 description 5
- 230000007358 intestinal barrier function Effects 0.000 description 5
- 230000033001 locomotion Effects 0.000 description 5
- 230000004962 physiological condition Effects 0.000 description 5
- 238000011321 prophylaxis Methods 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 230000001629 suppression Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 230000009885 systemic effect Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 description 4
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 4
- 235000005254 Allium ampeloprasum Nutrition 0.000 description 4
- 240000006108 Allium ampeloprasum Species 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 208000015943 Coeliac disease Diseases 0.000 description 4
- 208000011231 Crohn disease Diseases 0.000 description 4
- 206010061958 Food Intolerance Diseases 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- 102000016267 Leptin Human genes 0.000 description 4
- 108010092277 Leptin Proteins 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 235000020940 control diet Nutrition 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 4
- 229940039781 leptin Drugs 0.000 description 4
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 4
- PXUQTDZNOHRWLI-OXUVVOBNSA-O malvidin 3-O-beta-D-glucoside Chemical compound COC1=C(O)C(OC)=CC(C=2C(=CC=3C(O)=CC(O)=CC=3[O+]=2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1 PXUQTDZNOHRWLI-OXUVVOBNSA-O 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 239000002207 metabolite Substances 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 230000004584 weight gain Effects 0.000 description 4
- 235000019786 weight gain Nutrition 0.000 description 4
- 208000004998 Abdominal Pain Diseases 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 102000011690 Adiponectin Human genes 0.000 description 3
- 108010076365 Adiponectin Proteins 0.000 description 3
- 241000203069 Archaea Species 0.000 description 3
- 206010003645 Atopy Diseases 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 208000027244 Dysbiosis Diseases 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 206010017964 Gastrointestinal infection Diseases 0.000 description 3
- 241000590002 Helicobacter pylori Species 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 3
- 102000004722 NADPH Oxidases Human genes 0.000 description 3
- 108010002998 NADPH Oxidases Proteins 0.000 description 3
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 3
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 3
- 240000007594 Oryza sativa Species 0.000 description 3
- 235000007164 Oryza sativa Nutrition 0.000 description 3
- 241000700157 Rattus norvegicus Species 0.000 description 3
- 235000011720 Vaccinium uliginosum Nutrition 0.000 description 3
- 206010000059 abdominal discomfort Diseases 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 210000001789 adipocyte Anatomy 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000000090 biomarker Substances 0.000 description 3
- 235000013949 black currant juice Nutrition 0.000 description 3
- 150000001765 catechin Chemical class 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 208000021735 chronic enteritis Diseases 0.000 description 3
- 208000037976 chronic inflammation Diseases 0.000 description 3
- 230000006020 chronic inflammation Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000013872 defecation Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 230000000378 dietary effect Effects 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 239000000446 fuel Substances 0.000 description 3
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 3
- 150000003271 galactooligosaccharides Chemical class 0.000 description 3
- 238000007446 glucose tolerance test Methods 0.000 description 3
- 230000007407 health benefit Effects 0.000 description 3
- 229940037467 helicobacter pylori Drugs 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 208000002551 irritable bowel syndrome Diseases 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 229940127557 pharmaceutical product Drugs 0.000 description 3
- 229920000728 polyester Polymers 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- YQUVCSBJEUQKSH-UHFFFAOYSA-N protochatechuic acid Natural products OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 230000001953 sensory effect Effects 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 229910001220 stainless steel Inorganic materials 0.000 description 3
- 239000010935 stainless steel Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- BTQAJGSMXCDDAJ-UHFFFAOYSA-N 2,4,6-trihydroxybenzaldehyde Chemical compound OC1=CC(O)=C(C=O)C(O)=C1 BTQAJGSMXCDDAJ-UHFFFAOYSA-N 0.000 description 2
- KWCCUYSXAYTNKA-UHFFFAOYSA-N 3-O-methylgallic acid Chemical compound COC1=CC(C(O)=O)=CC(O)=C1O KWCCUYSXAYTNKA-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 206010000117 Abnormal behaviour Diseases 0.000 description 2
- 108010005094 Advanced Glycation End Products Proteins 0.000 description 2
- 241000234282 Allium Species 0.000 description 2
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 2
- 240000002234 Allium sativum Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 244000003416 Asparagus officinalis Species 0.000 description 2
- 235000005340 Asparagus officinalis Nutrition 0.000 description 2
- 231100000699 Bacterial toxin Toxicity 0.000 description 2
- 241000606219 Bacteroides uniformis Species 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 241000193403 Clostridium Species 0.000 description 2
- 208000012661 Dyskinesia Diseases 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 206010064147 Gastrointestinal inflammation Diseases 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 206010019708 Hepatic steatosis Diseases 0.000 description 2
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 208000015592 Involuntary movements Diseases 0.000 description 2
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 2
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 2
- 240000005561 Musa balbisiana Species 0.000 description 2
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 2
- 102000003945 NF-kappa B Human genes 0.000 description 2
- 108010057466 NF-kappa B Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 241000425347 Phyla <beetle> Species 0.000 description 2
- 208000001280 Prediabetic State Diseases 0.000 description 2
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 2
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 2
- 240000000111 Saccharum officinarum Species 0.000 description 2
- 235000007201 Saccharum officinarum Nutrition 0.000 description 2
- 241000209056 Secale Species 0.000 description 2
- 235000007238 Secale cereale Nutrition 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 244000098338 Triticum aestivum Species 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000000688 bacterial toxin Substances 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 239000003181 biological factor Substances 0.000 description 2
- 230000001055 chewing effect Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- YTMNONATNXDQJF-UBNZBFALSA-N chrysanthemin Chemical compound [Cl-].O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC2=C(O)C=C(O)C=C2[O+]=C1C1=CC=C(O)C(O)=C1 YTMNONATNXDQJF-UBNZBFALSA-N 0.000 description 2
- 229950001002 cianidanol Drugs 0.000 description 2
- 230000002566 clonic effect Effects 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 230000007140 dysbiosis Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 210000000744 eyelid Anatomy 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 208000010706 fatty liver disease Diseases 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 235000004611 garlic Nutrition 0.000 description 2
- 201000007116 gestational trophoblastic neoplasm Diseases 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 230000008776 intercellular pathway Effects 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 210000003750 lower gastrointestinal tract Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 244000005706 microflora Species 0.000 description 2
- 238000000324 molecular mechanic Methods 0.000 description 2
- 238000002552 multiple reaction monitoring Methods 0.000 description 2
- 230000017311 musculoskeletal movement, spinal reflex action Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 201000009104 prediabetes syndrome Diseases 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000001294 propane Substances 0.000 description 2
- 238000009256 replacement therapy Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 239000011343 solid material Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- JMSVCTWVEWCHDZ-UHFFFAOYSA-N syringic acid Chemical compound COC1=CC(C(O)=O)=CC(OC)=C1O JMSVCTWVEWCHDZ-UHFFFAOYSA-N 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 235000012431 wafers Nutrition 0.000 description 2
- YDIKCZBMBPOGFT-DIONPBRTSA-N (2s,3r,4s,5s,6r)-2-[5,7-dihydroxy-2-(4-hydroxy-3,5-dimethoxyphenyl)chromenylium-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol;chloride Chemical compound [Cl-].COC1=C(O)C(OC)=CC(C=2C(=CC=3C(O)=CC(O)=CC=3[O+]=2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1 YDIKCZBMBPOGFT-DIONPBRTSA-N 0.000 description 1
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- 206010027654 Allergic conditions Diseases 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 1
- 244000178937 Brassica oleracea var. capitata Species 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- RKWHWFONKJEUEF-GQUPQBGVSA-O Cyanidin 3-O-glucoside Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC2=C(O)C=C(O)C=C2[O+]=C1C1=CC=C(O)C(O)=C1 RKWHWFONKJEUEF-GQUPQBGVSA-O 0.000 description 1
- 102100031051 Cysteine and glycine-rich protein 1 Human genes 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- OIZFQAFWYYKPMR-PEVLUNPASA-N Delphinidin 3-O-glucoside Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)C=1[C-](c2cc(O)c(O)c(O)c2)[O+]c2c(c(O)cc(O)c2)C=1 OIZFQAFWYYKPMR-PEVLUNPASA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010061819 Disease recurrence Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 206010016100 Faeces discoloured Diseases 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000004101 Gaylussacia dumosa Nutrition 0.000 description 1
- 102000012004 Ghrelin Human genes 0.000 description 1
- 101800001586 Ghrelin Proteins 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 206010023644 Lacrimation increased Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- PXUQTDZNOHRWLI-JJYSZZJESA-O Oenin Natural products O(C)c1c(O)c(OC)cc(-c2c(O[C@H]3[C@@H](O)[C@H](O)[C@H](O)[C@@H](CO)O3)cc3c(O)cc(O)cc3[o+]2)c1 PXUQTDZNOHRWLI-JJYSZZJESA-O 0.000 description 1
- 201000002451 Overnutrition Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 206010035039 Piloerection Diseases 0.000 description 1
- 206010062519 Poor quality sleep Diseases 0.000 description 1
- 241000192142 Proteobacteria Species 0.000 description 1
- 235000014360 Punica granatum Nutrition 0.000 description 1
- 244000294611 Punica granatum Species 0.000 description 1
- 235000001537 Ribes X gardonianum Nutrition 0.000 description 1
- 235000001535 Ribes X utile Nutrition 0.000 description 1
- 235000016919 Ribes petraeum Nutrition 0.000 description 1
- 244000281247 Ribes rubrum Species 0.000 description 1
- 235000002355 Ribes spicatum Nutrition 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 240000007651 Rubus glaucus Species 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 208000004509 Tooth Discoloration Diseases 0.000 description 1
- 206010044032 Tooth discolouration Diseases 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 241001593968 Vitis palmata Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 229930014669 anthocyanidin Natural products 0.000 description 1
- 235000008758 anthocyanidins Nutrition 0.000 description 1
- 230000000489 anti-atherogenic effect Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000005549 barrier dysfunction Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000021029 blackberry Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 108091006374 cAMP receptor proteins Proteins 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical group OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000012578 cell culture reagent Substances 0.000 description 1
- 230000004656 cell transport Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 238000013479 data entry Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- XENHPQQLDPAYIJ-PEVLUNPASA-O delphinidin 3-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC2=C(O)C=C(O)C=C2[O+]=C1C1=CC(O)=C(O)C(O)=C1 XENHPQQLDPAYIJ-PEVLUNPASA-O 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 230000009699 differential effect Effects 0.000 description 1
- 208000019836 digestive system infectious disease Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000013931 endocrine signaling Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000001842 enterocyte Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- NWKFECICNXDNOQ-UHFFFAOYSA-N flavylium Chemical compound C1=CC=CC=C1C1=CC=C(C=CC=C2)C2=[O+]1 NWKFECICNXDNOQ-UHFFFAOYSA-N 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 238000003500 gene array Methods 0.000 description 1
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940038487 grape extract Drugs 0.000 description 1
- 235000019674 grape juice Nutrition 0.000 description 1
- 235000021021 grapes Nutrition 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 230000007166 healthy aging Effects 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000043557 human IFNG Human genes 0.000 description 1
- 102000057041 human TNF Human genes 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 230000004317 lacrimation Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000010150 least significant difference test Methods 0.000 description 1
- 230000004446 light reflex Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000006372 lipid accumulation Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000013227 male C57BL/6J mice Methods 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 231100000324 minimal toxicity Toxicity 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000037230 mobility Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- GXPTVXHTZZVLMQ-GCGJSEPQSA-N myrtillin Natural products O[C@H]1O[C@@H](OCC2=C(OC3=CC(=O)C=C(O)C3=C2)c4cc(O)c(O)c(O)c4)[C@H](O)[C@@H](O)[C@@H]1O GXPTVXHTZZVLMQ-GCGJSEPQSA-N 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000003188 neurobehavioral effect Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 231100000062 no-observed-adverse-effect level Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015816 nutrient absorption Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- AXKKKZRHURPRMF-UHFFFAOYSA-N oenin chloride Natural products COC1=CC(=C2Oc3cc(O)cc(O)c3C=C2OC4OC(CO)C(O)C(O)C4O)C=C(OC)C1=O AXKKKZRHURPRMF-UHFFFAOYSA-N 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 235000020823 overnutrition Nutrition 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- ABVCUBUIXWJYSE-GQUPQBGVSA-O pelargonidin 3-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC2=C(O)C=C(O)C=C2[O+]=C1C1=CC=C(O)C=C1 ABVCUBUIXWJYSE-GQUPQBGVSA-O 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 125000000538 pentafluorophenyl group Chemical group FC1=C(F)C(F)=C(*)C(F)=C1F 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 235000009048 phenolic acids Nutrition 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000005371 pilomotor reflex Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013525 pomegranate juice Nutrition 0.000 description 1
- 238000009597 pregnancy test Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 238000011112 process operation Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000001179 pupillary effect Effects 0.000 description 1
- 235000021013 raspberries Nutrition 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 235000021012 strawberries Nutrition 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- YIBXWXOYFGZLRU-UHFFFAOYSA-N syringic aldehyde Natural products CC12CCC(C3(CCC(=O)C(C)(C)C3CC=3)C)C=3C1(C)CCC2C1COC(C)(C)C(O)C(O)C1 YIBXWXOYFGZLRU-UHFFFAOYSA-N 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 210000004888 thoracic abdominal cavity Anatomy 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 230000036367 tooth discoloration Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 241001446247 uncultured actinomycete Species 0.000 description 1
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 1
- WKOLLVMJNQIZCI-UHFFFAOYSA-N vanillic acid Chemical compound COC1=CC(C(O)=O)=CC=C1O WKOLLVMJNQIZCI-UHFFFAOYSA-N 0.000 description 1
- TUUBOHWZSQXCSW-UHFFFAOYSA-N vanillic acid Natural products COC1=CC(O)=CC(C(O)=O)=C1 TUUBOHWZSQXCSW-UHFFFAOYSA-N 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 235000014101 wine Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/40—Shaping or working of foodstuffs characterised by the products free-flowing powder or instant powder, i.e. powder which is reconstituted rapidly when liquid is added
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/733—Fructosans, e.g. inulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
- A23V2200/3202—Prebiotics, ingredients fermented in the gastrointestinal tract by beneficial microflora
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/2104—Anthocyanins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/2106—Bilberries, blueberries
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/28—Oligosaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/28—Oligosaccharides
- A23V2250/284—Oligosaccharides, non digestible
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/50—Polysaccharides, gums
- A23V2250/502—Gums
- A23V2250/5062—Inulin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Diabetes (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
Description
この出願の発明に関連する先行技術文献情報としては、以下のものがある(国際出願日以降国際段階で引用された文献及び他国に国内移行した際に引用された文献を含む)。
(先行技術文献)
(特許文献)
(特許文献1) 欧州特許出願公開第2682005号明細書
(特許文献2) 米国特許出願公開第2014/0128333号明細書
(特許文献3) 米国特許出願公開第2007/0243268号明細書
(特許文献4) 米国特許出願公開第2008/0026058号明細書
(非特許文献)
(非特許文献1) PEREZ-VICENTE,ANTONIO et al.,‘In vitro gastrointestinal digestion study of pomegranate juice phenolic compounds,anthocyanins,and vitamin C’,Journal of agricultural and food chemistry,10 April 2002,Vol.50,No.8,pp.2808-2312
本明細書に提示する一実施形態では、腸過透過性を治療するのに十分な量で、シアニジンおよびデルフィニジンを併用して有する、腸の健康を促進する組成物がある。
アントシアニン(AC)と、様々なタイプのACを含み、AC含有量の多い抽出物7種類の性能を測定し、Caco-2細胞単層の腫瘍壊死因子α(TNFα)で誘導される透過性亢進を抑制する性能を決定した。前記ACも検討し、ACの化学構造/立体構造の関係を決定し、前記AC含有量の程度を、Caco-2細胞単層のTNFαで誘導される透過性亢進を抑制する前記ACの保護効果の程度に対して決定した。
Caco-2細胞はアメリカン・タイプ・カルチャー・コレクション(米国マサチューセッツ州Rockville)から入手した。
化学構造の解像は、ChemBio3D Ultra 11.0.1(Cambridge Scientific Computing, Inc.)で利用できる所定の方法を利用し、Allingerに従って、分子力学(MM2)により行った。前記アントシアニンの構造は図5~9に示す。
TEER=(Rm-Ri)xA (I)
として計算し、式中、Rm:膜貫通抵抗、Ri:無細胞培地の内因性抵抗、およびA:膜の表面積(cm2)であった。
HPLC-MS/MSで評価した様々な抽出物のAC濃度を表5に示す。
毒性試験は、シアニジン、デルフィニジン、およびプレバイオティック混合物を有する組成物をWistarラットに90日間経口投与後の毒性を判定するために行った。本試験では、用量反応関係および無毒性量の測定も評価した。
健康なWistarラット(Rattus norvegicus)をランダムに選択し、本試験に入れた。6~8週齢の雌ラット60匹および雄ラット60匹を6群に割り付けた。
選択したラットを獣医師が検査し、初回投与前に5日間試験条件に順化させた。コンピュータ作成した無作為化表により、試験開始前にラットを6群に割り付けた。ラットの体重のばらつきは最小限であり、平均体重の±20%を超えなかった。
試験中、身体所見はほとんど正常であり、および/または全群で一貫しており、毒性はわずかであると判断された。間代性または強直性行動は認められなかった。唯一の奇異な行動は紙を噛む行動であった。紙を噛む行動は、対照群を含むすべての群で毎日観察された。接触反応および接近反応は速かった。テールピンチは尻込みとして観察し、瞳孔反応は正常であった。
高脂肪食により誘導した肥満のマウスモデルを用い、アントシアニンが豊富な食事が肥満で誘導される腸の炎症、腸バリア透過性の亢進、およびインスリン抵抗性を予防および/または軽減する潜在的性能を検討した。アントシアニン補充が高脂肪食で誘導される(a)腸の炎症、(b)腸透過性、(c)腸微生物叢、および(d)アントシアニン代謝の変化に及ぼす影響を評価した。
Jackson laboratoriesから60匹の健康な雄C57BL/6Jマウス(20~23g)を入手し、標準的なステンレス鋼ケージで飼育した(4匹/ケージ)。マウス用のケージと床敷を使用し、強化環境を提供した。マウスは1週間順化してから、投与を開始した。マウスをグループ分けし(10匹/群/時点)、対照食、対照食+アントシアニン、高脂肪食、高脂肪食+2%アントシアニン、高脂肪食+20%アントシアニン、または高脂肪食+40%アントシアニンのいずれか1種類を与えた。これらの食餌の成分を以下に説明する。
マウスをステンレス鋼ケージで飼育した。1ケージで4匹のマウスを飼育した。各群のマウスは10匹とした。
前記食餌療法中、各群のマウスは着実に体重を増加させた。最も体重増加が大きかったのは0~8週目で、最も増加が少なかったのは8~12週目であった。高脂肪食および高脂肪食+2% ACを与えたマウスは、全体的に試験中最も体重を増加させた。
この試験は、アントシアニン、イヌリン、およびプレバイオティックファイバーを含む組成物が肥満成人の微生物構成に与える影響を決定するために実施した。
試験開始2週間前に初期スクリーニングを実施した。前記初期スクリーニング中、参加候補者は病歴を照査し、すべての併用療法を示し、選択基準および除外基準を特定した。参加候補者の安静時血圧、心拍数、体重、身長、および体格指数も測定した。適宜、妊娠検査を行った。
当初試験に登録された51例中46例の参加者が試験を終了した。4例の参加者が0日目後、29日目に最初の比較測定を行う前に脱落した。1例は29日目~57日目の診察の間に脱落した。
前記組成物を補充した参加者は、フィルミクテス:バクテロイデス比の変化で示されるとおり、その微生物構成に良好な変化が生じた。図44。前記比は4.98から1.45に低下した(フィルミクテス門は74.9%から59%に低下、バクテロイデス門は13.8%から34.5%に上昇した)。さらに、放線菌門は8.5%から3.4%に低下した。前記補充後、合計8門(細菌6門、古細菌1門、およびその他1門)および40属(放線菌7属、バクテロイデス門8属、ユーリ古細菌1属、フィルミクテス門2属、およびプロテオバクテリア門3属)が変化した。
ベースラインと比較し、6週目および7週目でブリストル便性状スコアに5%の上昇が認められた。排便回数は試験中変化しなかったが、用便習慣は改善した。図46。参加者は排便前(33%)および排便中止時(51~54%)のいきみが減少し、不完全な排便が減少したと報告した。
参加者の腹部膨満はベースラインと比較し、3週目から8週目に減少した(4週目41%、5週目52%、および8週目50%)。図47。
全体として、本試験は、前記製剤が軽度から中等度の肥満であるが、それ以外はまだ健康な個人の腸微生物叢を改善できることを示した。試験中、参加者には前記フィルミクテス門の有意な減少とバクテロイデス門の割合の有意な増加がみられた。フィルミクテス:バクテロイデス比は補充療法により0日目から57日目まで低下した。前記比は4.98から1.45に変化した。さらに、放線菌レベルが低下した。これら3門は、ベースライン時(97.2%)および補充療法後(96.9%)では、前記細菌構成の約97%を構成する。
Claims (20)
- 腸の健康を促進する組成物であって、シアニジングリコシドおよびデルフィニジングリコシドの組み合わせを前記組成物の5wt%~50wt%の量で有し、腸過透過性を抑制し、かつ腸透過性を維持する、組成物。
- 請求項1記載の組成物において、前記シアニジングリコシドおよび前記デルフィニジングリコシドの少なくとも1つの原料が黒米抽出物成分、ブルーベリー抽出物成分、クロスグリ抽出物成分、クロウベリー抽出物成分、ビルベリー抽出物成分、ブラックチョークベリー抽出物成分、またはそれらの組み合わせに由来する組成物。
- 請求項2記載の組成物において、前記黒米抽出物成分が、前記組成物の2.5wt%~20wt%を有し、かつ10wt%~30wt%のアントシアニン含有量を有する組成物。
- 請求項2記載の組成物において、前記黒米抽出物成分がOryza sativa L.に由来する組成物。
- 請求項2記載の組成物において、前記ブルーベリー抽出物成分が、前記組成物の1wt%~30wt%を有し、かつ0.5wt%~30wt%のアントシアニン含有量を有する組成物。
- 請求項2記載の組成物において、前記ブルーベリー抽出物成分がVaccinium uliginosum L.に由来する組成物。
- 請求項2記載の組成物において、前記クロスグリ抽出物成分が、前記組成物の0.5wt%~15wt%を有し、かつ20wt%~40wt%のアントシアニン含有量を有する組成物。
- 請求項2記載の組成物において、前記クロスグリ抽出物成分がRibes nigrumに由来する組成物。
- 請求項2記載の組成物において、前記クロウベリー抽出物成分が、前記組成物の1wt%~30wt%を有し、かつ40wt%~50wt%のアントシアニン含有量を有する組成物。
- 請求項2記載の組成物において、前記クロウベリー抽出物成分がEmpetrum nigrumに由来する組成物。
- 請求項2記載の組成物において、前記ビルベリー抽出物成分が、前記組成物の0.5wt%~30wt%を有し、かつ1wt%~30wt%のアントシアニン含有量を有する組成物。
- 請求項2記載の組成物において、前記ビルベリー抽出物成分がVaccinium m yrtillusに由来する組成物。
- 請求項2記載の組成物において、前記シアニジングリコシドおよび前記デルフィニジングリコシドの少なくとも1つの原料が黒米抽出物成分、ブルーベリー抽出物成分、およびクロスグリ抽出物成分の組み合わせに由来する組成物。
- 請求項13記載の組成物において、前記黒米抽出物成分、前記ブルーベリー抽出物成分、および前記クロスグリ抽出物成分が1:1:1の比を有する組成物。
- 請求項1記載の組成物であって、さらに、プレバイオティック混合物を有する組成物。
- 請求項15記載の組成物において、前記プレバイオティック混合物がイヌリン、またはフルクトオリゴ糖、またはそれらの組み合わせを有する組成物。
- 請求項16記載の組成物において、前記イヌリンがβ(2-1)結合で結合したフルクトース単位を持つオリゴ糖および多糖類を有するチコリーイヌリンであり、前記フルクトオリゴ糖が短鎖フルクトオリゴ糖(DP≦5)である組成物。
- 請求項16記載の組成物において、前記イヌリンが、前記組成物の15wt%~60wt%を有し、前記フルクトオリゴ糖が、前記組成物の10wt%~40wt%を有する組成物。
- 請求項16記載の組成物であって、さらに、イヌリンおよびフルクトオリゴ糖のプレバイオティック混合物を有する組成物。
- 請求項19記載の組成物において、前記イヌリンおよびフルクトオリゴ糖が、前記組成物の55wt%~95wt%を有する組成物。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021189726A JP7473516B2 (ja) | 2016-10-27 | 2021-11-22 | 腸の健康を促す組成物 |
JP2024063716A JP2024099590A (ja) | 2016-10-27 | 2024-04-11 | 腸の健康を促す組成物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2016/059226 WO2018080510A1 (en) | 2016-10-27 | 2016-10-27 | Intestinal health promoting compositions |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021189726A Division JP7473516B2 (ja) | 2016-10-27 | 2021-11-22 | 腸の健康を促す組成物 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2019534331A JP2019534331A (ja) | 2019-11-28 |
JP2019534331A5 JP2019534331A5 (ja) | 2021-05-06 |
JP7011885B2 true JP7011885B2 (ja) | 2022-01-27 |
Family
ID=62023893
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019545873A Active JP7011885B2 (ja) | 2016-10-27 | 2016-10-27 | 腸の健康を促す組成物 |
JP2021189726A Active JP7473516B2 (ja) | 2016-10-27 | 2021-11-22 | 腸の健康を促す組成物 |
JP2024063716A Pending JP2024099590A (ja) | 2016-10-27 | 2024-04-11 | 腸の健康を促す組成物 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021189726A Active JP7473516B2 (ja) | 2016-10-27 | 2021-11-22 | 腸の健康を促す組成物 |
JP2024063716A Pending JP2024099590A (ja) | 2016-10-27 | 2024-04-11 | 腸の健康を促す組成物 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20190255134A1 (ja) |
JP (3) | JP7011885B2 (ja) |
KR (1) | KR20190079641A (ja) |
CN (1) | CN110636760B (ja) |
WO (1) | WO2018080510A1 (ja) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7011885B2 (ja) | 2016-10-27 | 2022-01-27 | エヌエスイー プロダクツ、インク. | 腸の健康を促す組成物 |
KR102178556B1 (ko) * | 2019-03-21 | 2020-11-13 | 강원대학교산학협력단 | 마늘껍질 추출물을 포함하는 장내균총 개선용 프리바이오틱스 조성물 및 이를 포함하는 기능성 식품 |
CN110283754B (zh) * | 2019-07-11 | 2021-02-02 | 中国科学院北京基因组研究所 | 用于类风湿关节炎炎症状态评估及预后评价的肠道微生物菌群 |
IT201900019325A1 (it) * | 2019-10-18 | 2021-04-18 | Ghs Gemelli Health System S R L | Miscela comprendente estratti di frutti, e polifenoli estratti da foglie o frutti di Olea Europaea L. e inulina e uso di tale composizione nel trattamento di malattie infiammatorie acute e croniche, localizzate o sistemiche, o conseguenti ad un’ischemia o a un’alterazione della funzionalità dell’endotelio vasale |
KR20210156445A (ko) | 2020-06-18 | 2021-12-27 | 종근당건강 주식회사 | 들쭉나무 열매 분말 또는 추출물을 함유하는 장내 환경 개선용 조성물 |
CN115645429B (zh) * | 2022-12-12 | 2023-05-16 | 汤臣倍健股份有限公司 | 一种花色苷组合物及其应用 |
WO2024148202A1 (en) * | 2023-01-04 | 2024-07-11 | Nse Products, Inc. | Metabolic health promoting compositions |
CN116790402B (zh) * | 2023-01-14 | 2024-05-14 | 西北农林科技大学 | 一株具有抗炎特性的单形拟杆菌菌株、培养方法及应用 |
CN117085117B (zh) * | 2023-09-14 | 2024-03-12 | 浙江花开星辰生物科技有限公司 | 一种洋甘菊提取物的抗幽门螺旋杆菌组合物及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004099578A (ja) | 2002-09-04 | 2004-04-02 | Oriza Yuka Kk | 美肌用組成物 |
JP2008271878A (ja) | 2007-04-27 | 2008-11-13 | Wakasa Seikatsu:Kk | 新規飲食品 |
JP2014528925A (ja) | 2011-08-17 | 2014-10-30 | マイクロバイオーム セラピューティクス,エルエルシー | バクテロイデス門の胃腸管微生物相対フィルミクテス門の微生物相の比を上昇させるための組成物および製剤の使用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100776465B1 (ko) * | 1999-08-27 | 2007-11-16 | 미시간 스테이트 유니버시티 | 천연 사이클로옥시게나제 저해물질을 함유한 식이요법용보조식품 |
US8337914B2 (en) * | 2002-02-27 | 2012-12-25 | Access Business Group International Llc | Dietary food supplement containing natural cyclooxygenase inhibitors and methods for inhibiting pain and inflammation |
AU2006311552A1 (en) * | 2005-11-07 | 2007-05-18 | Jaffe, Russell M | Compositions for regulating intestinal disorders and methods of use thereof |
EP1882473A1 (en) * | 2006-07-28 | 2008-01-30 | Indena S.P.A. | Use of anthocyanosides to prepare formulations for the treatment of mucositis induced by antitumoral drugs |
EP2682005A1 (en) * | 2012-07-05 | 2014-01-08 | Symrise AG | A dietary supplement composition |
EP2710901A1 (en) * | 2012-09-20 | 2014-03-26 | Symrise AG | Dietary supplement compositions |
US20140128333A1 (en) * | 2012-11-02 | 2014-05-08 | Maqui New Life S.A. | Compounds, Compositions, and Methods for Decreasing Intestinal Glucose Uptake and Inducing Incretin Release |
RU2683680C2 (ru) * | 2013-03-15 | 2019-04-01 | Марс, Инкорпорейтед | Съедобный жевательный продукт для домашних животных и способ его изготовления |
JP7011885B2 (ja) | 2016-10-27 | 2022-01-27 | エヌエスイー プロダクツ、インク. | 腸の健康を促す組成物 |
-
2016
- 2016-10-27 JP JP2019545873A patent/JP7011885B2/ja active Active
- 2016-10-27 KR KR1020197015224A patent/KR20190079641A/ko not_active Application Discontinuation
- 2016-10-27 WO PCT/US2016/059226 patent/WO2018080510A1/en active Application Filing
- 2016-10-27 US US16/346,100 patent/US20190255134A1/en active Pending
- 2016-10-27 CN CN201680091887.7A patent/CN110636760B/zh active Active
-
2021
- 2021-11-22 JP JP2021189726A patent/JP7473516B2/ja active Active
-
2024
- 2024-04-11 JP JP2024063716A patent/JP2024099590A/ja active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004099578A (ja) | 2002-09-04 | 2004-04-02 | Oriza Yuka Kk | 美肌用組成物 |
JP2008271878A (ja) | 2007-04-27 | 2008-11-13 | Wakasa Seikatsu:Kk | 新規飲食品 |
JP2014528925A (ja) | 2011-08-17 | 2014-10-30 | マイクロバイオーム セラピューティクス,エルエルシー | バクテロイデス門の胃腸管微生物相対フィルミクテス門の微生物相の比を上昇させるための組成物および製剤の使用 |
Non-Patent Citations (3)
Title |
---|
天然薬物事典,第1刷,株式会社廣川書店,1986年,第24-25頁 |
小川健二郎,学位論文,ベリー果実のアントシアニン分析と各種細胞障害に対するビルベリーの保護作用に関する薬理学的研究,乙358号,岐阜薬科大学,2014年,第1-28頁,2014年9月ダウンロード有り |
日本調理科学会誌,1999年,Vol. 32, No. 4,pp. 81-87 (367-373) |
Also Published As
Publication number | Publication date |
---|---|
WO2018080510A1 (en) | 2018-05-03 |
CN110636760A (zh) | 2019-12-31 |
JP2019534331A (ja) | 2019-11-28 |
JP2022036990A (ja) | 2022-03-08 |
JP2024099590A (ja) | 2024-07-25 |
US20190255134A1 (en) | 2019-08-22 |
JP7473516B2 (ja) | 2024-04-23 |
CN110636760B (zh) | 2023-04-14 |
KR20190079641A (ko) | 2019-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7011885B2 (ja) | 腸の健康を促す組成物 | |
JP6936932B2 (ja) | フラボノイド組成物及び使用方法 | |
JP5877902B2 (ja) | バクテロイデス門の胃腸管微生物相対フィルミクテス門の微生物相の比を上昇させるための組成物および製剤の使用 | |
EP2124972B1 (de) | Verwendung einer zusammensetzung aus mineralstoffen und gegebenenfalls acetogenen und/oder butyrogenen bakterien zur vermeidung oder reduzierung von gasbildung im dickdarm eines säugetiers und dadurch bedingter abdominaler beschwerden | |
Chen et al. | Anti-diabetic and anti-obesity: Efficacy evaluation and exploitation of polyphenols in fruits and vegetables | |
CN105228627A (zh) | 亮氨酸和烟酸降低脂质水平 | |
WO2018090983A1 (zh) | 改善肠道菌群的皂苷类化合物、制备方法及其应用 | |
US20220322719A1 (en) | Intestinal health promoting compositions | |
WO2015200842A1 (en) | Composition comprising metformin and a microbiome modulator | |
CA2902248A1 (en) | Activated soy pod fiber | |
US11266668B2 (en) | Dietary supplement for glycemia control and diabetes prevention | |
CN115697366A (zh) | 用于患有子宫内膜异位症的对象的组合物及组合 | |
Fiore et al. | Bioactive compounds in childhood obesity and associated metabolic complications: Current evidence, controversies and perspectives | |
US20070248621A1 (en) | Food product containing policosanols | |
WO2015127314A1 (en) | Activated soy pod fiber | |
US20200146325A1 (en) | Dietary supplement for glycemia control and diabetes prevention | |
CA2987143A1 (en) | Composition and uses thereof | |
JP4371431B2 (ja) | 抗アレルギー性組成物 | |
Jenkins et al. | Herbal Infusions and Women’s Health: A Review of Findings with a Focus on Human Studies on Specific Infusions with Studies on Extracts to Evaluate Mechanisms | |
CN104642869B (zh) | 一种具有通便功能的保健食品 | |
Bagchi et al. | Phytoceutical-based Traditional Weight Loss Strategies for Management of Body Recomposition: Common Misconceptions and Novel Technological Breakthroughs | |
US20230030835A1 (en) | Polyphenol compositions and uses thereof | |
Salden et al. | Effect of hesperidin 2S supplementation on systemic and intestinal metabolic parameters in subjects at risk for metabolic syndrome: a randomized controlled trial | |
Tafti et al. | Efficacy of Herbal Supplementation of Purslane Freeze-dried Juice for Weight Loss: An 8-week Randomized, Double-blind, Placebo-controlled Clinical Trial | |
Dahiya et al. | Gastrointestinal Tract and Digestion Challenges in Aging and Nutraceuticals |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191025 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20191025 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201020 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210119 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210322 |
|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20210322 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20210720 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211122 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20211122 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20211216 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20211221 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220111 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220115 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7011885 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |